Chemotherapy Resistance in Lung Cancer.

Chemotherapy Resistance in Lung Cancer. Adv Exp Med Biol. 2016;893:189-209 Authors: Kim ES Abstract Despite a growing interest in development of non-cytotoxic targeted agents, systemic chemotherapy is still the mainstay of treatment for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). However, chemotherapy resistance limits our ability to effectively treat advanced lung cancer. Some lung tumors are intrinsically resistant to chemotherapy, and in virtually all cases, even the initial responders rapidly develop acquired resistance. While targeting histology could result in enhanced tumor sensitivity to a particular chemotherapeutic agent, better understanding of molecular determinants of chemotherapy sensitivity/resistance would be critically important. Development of predictive biomarkers to personalize chemotherapeutic agents and combining novel agents targeting specific resistance pathways with standard chemotherapy could be some promising strategies to overcome chemotherapy resistance in lung cancer. In this chapter, we will discuss some key mechanisms of resistance for commonly used chemotherapeutic agents in lung cancer. PMID: 26667345 [PubMed - in process]
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research

Related Links:

Lung cancer is the leading cause of cancer-related deaths worldwide and can be broadly classified into two types: non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). The former represents 85% of all lung cancer [1].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
This article is protected by copyright. All rights reserved. PMID: 31381177 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Pharmacology and Physiology - Category: Drugs & Pharmacology Authors: Tags: Clin Exp Pharmacol Physiol Source Type: research
Lung cancer is one of the leading causes of cancer-related deaths in the world. In 2012, lung cancer was responsible for approximately 1.6 million deaths worldwide [1]. Lung cancer may be broadly divided into small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC), with many distinct histology subtypes in the latter [2]. In contrast to SCLC, where chemotherapy provides the mainstay of treatment with mostly palliative intent, surgery is routinely performed in early stage NSCLC with a curative intent [2,3].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
This article reviewed the predictive value of TMB and its limitations in the field of immunotherapy for lung cancer. DOI: 10.3779/j.issn.1009-3419.2019.06.08
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
nning Schmidt Lung cancer is the leading cause of cancer-related deaths worldwide. With a focus on histology, there are two major subtypes: Non-small cell lung cancer (NSCLC) (the more frequent subtype), and small cell lung cancer (SCLC) (the more aggressive one). Even though SCLC, in general, is a chemosensitive malignancy, relapses following induction therapy are frequent. The standard of care treatment of SCLC consists of platinum-based chemotherapy in combination with etoposide that is subsequently enhanced by PD-L1-inhibiting atezolizumab in the extensive-stage disease, as the addition of immune-checkpoint inhibit...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Lung cancer is the leading cause of cancer related mortality globally and is classified as either Small Cell Lung Cancer (SCLC) or Non-Small Cell Lung Cancer (NSCLC) upon pathology review. [1,2] The main histologic types of NSCLC include squamous cell carcinoma and adenocarcinoma. [2] The majority of patients have non-curable disease stage at the time of diagnosis. Advances in systemic treatments including chemotherapy, targeted therapies and immune check point inhibitors have improved prognosis in recent years.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Conclusion: Our data supports that never/ever smoker patients with small-cell lung cancer have better prognosis compared to their smoker counterparts. Further, patients with never/ever smoking history who present with small-cell lung cancer have a different mutation profile compared with smokers, including a high frequency of EGFR, MET, and SMAD4 mutations. Further studies are required to assess whether the differential mutation profile is a consequence of a diverse pathological mechanism for disease onset. Introduction Lung cancer is the most common neoplasia worldwide. Aside from the high incidence, lung cancer a...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In this study, 7 patients with transformation of SCLC from advanced lung adenocarcinoma (ADC) were analyzed retrospectively and the clinical pathology, imaging characteristics and treatment were analyzed. We identified 7 patients with primary lung ADC that showed transformation to SCLC on second biopsy during a 6-year period. Clinicopathologic information was analyzed and EGFR mutation results were performed in initial biopsy samples. Seven patients showed transformation from ADC to SCLC, of which 6 patients were 19 del EGFR mutation, only 1 patient is L858R mutations. The imaging forms did not have the typical imaging f...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Our study shows that retinoblastoma (RB1) mutation is associated with decreased overall survival in patients with locally advanced and advanced non small cell lung cancer. We also show thatRB1 mutation correlates with lack of response to immunotherapy. AbstractThe retinoblastoma gene (RB1) encodes the retinoblastoma (RB) pocket protein that plays an important role in cell cycle progression. Here we determine the frequency and prognostic significance ofRB1 mutation in non small cell lung cancer (NSCLC), restricting inclusion to Stage III and IV patients with linked genomic and clinical data. The primary outcome was median o...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Lung cancer is the leading cause of cancer-related deaths worldwide. The United States accounts for the third-largest number of new lung cancer cases worldwide. Because of non-specific symptoms, the majority of lung cancers are typically diagnosed at extensive stage. Compared with non-small cell lung cancer (NSCLC), small-cell lung cancer (SCLC) has inferior prognosis [1]. Although nearly all SCLC have inactivation or loss of TP53 and RB1, as well as other mutations, the target driven gene is not definitive.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Molecular Biology | Non-Small Cell Lung Cancer | Research | Small Cell Lung Cancer